Skip to content

NEUMORA THERAPEUTICS, INC.

NMRA

CIK 0001885522

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$230.94M
+2.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.40
+5.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$181.97M
Q1 May 2026
Cash
$147.07M
Q1 May 2026
Total Debt
$112.96M
Q1 May 2026
Shares Outstanding
185.28M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings